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ABSTRACT: Cellular delivery of DNA vectors for the expression
of therapeutic proteins is a promising approach to treat monogenic
disorders or cancer. Significant efforts in a preclinical and clinical
setting have been made to develop potent nonviral gene delivery
systems based on lipoplexes composed of permanently cationic
lipids. However, transfection efficiency and tolerability of such
systems are in most cases not satisfactory. Here, we present a one-
pot combinatorial method based on double-reductive amination for
the synthesis of short-chain aminolipids. These lipids can be used
to maximize the DNA vector delivery when combined with the
cationic lipid 1,2-dioleoyl-3-trimethylammonium propane
(DOTAP). We incorporated various aminolipids into such
lipoplexes to complex minicircle DNA and screened these systems
in a human liver-derived cell line (HuH7) for gene expression and cytotoxicity. The lead aminolipid AL-A12 showed twofold
enhanced gene delivery and reduced toxicity compared to the native DOTAP:cholesterol lipoplexes. Moreover, AL-A12-containing
lipoplexes enabled enhanced transgene expression in vivo in the zebrafish embryo model.
■ INTRODUCTION
Delivery of genetic material to diseased cells is of growing
clinical interest. Many inherited liver diseases including
Crigler−Najjar syndrome or Gilbert’s syndrome are associated
with genetic defects leading to loss of function of proteins or
low levels of enzymatic activity.1−8 Gene therapy enables the
introduction of genetic material (e.g., DNA vectors) encoding
for a therapeutic protein, thereby restoring physiological
functions. Alternatively, the expression of tumor suppressors,
proapoptotic or oncotoxic proteins, offers an interesting option
for the treatment of malignant disorders.9−16
In recent years, various nonviral delivery systems have been
investigated in preclinical and clinical settings for the delivery
of recombinant DNA.17 Electrostatic interaction of cationic
lipids and negatively charged DNA vectors of virtually any size
induces condensation. The resulting lipoplexes are formed
spontaneously. Their preparation and handling are simple and
cost-effective. Moreover, lipoplexes allow for a straightforward
transfer “from bench to large-scale production” compared to
viral vectors18 without the risk for insertion of genetic material
into the host’s genome as shown for adeno-associated virus
vectors.19−21 Although cationic lipids overcome some of the
limitations described for viral vectors, they encompass some
disadvantages: The permanent positive charge of cationic lipids
is associated with cytotoxicity,22 and lipoplex systems generally
lack efficiency compared to viral vectors.23,24 As a result, only a
few types of cationic lipids have entered clinical trials. In 2017,
lipofection (i.e., the introduction of exogenous genetic material
by means of lipid-based transfection reagents) accounted for
only 4.5% of all clinical trials involving gene therapy.25 As one
of the exceptions, 1,2-dioleoyl-3-trimethylammonium propane
and cholesterol (DOTAP:chol)-based lipoplexes have been
clinically investigated for the treatment of various diseases
including lung cancer, breast cancer, prostate cancer, or
hepatocellular carcinoma.9,13,15,16,26,27 The cationic charge of
DOTAP:chol lipoplexes enables facilitated cellular interactions
and also accounts for decreased cell viability.24,28 Therefore, as
observed for many lipoplexes, the use of DOTAP:chol systems
is limited by poor transfection efficiency and cytotoxic
effects.29−32
The aim of the present study was to maximize the potency of
clinically tested DOTAP:chol lipoplexes while reducing
toxicity. Based on our finding that short-chain (C8−C12)
amide lipidoids are potential carriers for siRNA,33 a
combination of short-chain aminolipids and DOTAP:chol-
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based lipoplexes was explored to enhance DNA vector delivery.
It is noteworthy that enhanced gene silencing and reduced
cytotoxic potential were demonstrated for polymeric nano-
particles after combination with natural polyphenols and
polyphenol inspired polycatechols.34,35 In view of these results,
a combinatorial library of different types of aminolipids with
chain lengths of C10 or C12 and various headgroups, including
aliphatic and heterocyclic functional groups, was synthesized
by double-reductive amination. The designed aminolipids were
incorporated into DOTAP:chol lipoplexes and screened in
vitro for transfection efficiency and cellular toxicity. The most
promising aminolipid-containing system was then compared to
DOTAP:chol lipoplexes for in vivo transfection efficiency in the
zebrafish embryo model.
■ MATERIALS AND METHODS
Materials. Text adopted from Neuhaus et al.36 The starting
compounds and solvents were purchased from Sigma-Aldrich
(St. Louis, MO), Honeywell Fluka (Fisher Scientific AG,
Reinach, Switzerland), ABCR (Zug, Switzerland), TCI
Deutschland GmbH (Eschborn, Germany), or Acros Organics
(Thermo Fisher Scientific, Geel, Belgium) and were used
without further purification. For reactions under inert gas
conditions, the solvent dichloromethane (DCM) was dried
over molecular sieves 4 Å and degassed afterward. Column
chromatography was carried out using 230−400 mesh, 60 Å
silica gel (Chemie Brunschwig AG, Basel, Switzerland). TLC
plates (Merck, Darmstadt, Germany, Silica gel 60 F254) were
developed with KMnO4 solution. 1H and 13C NMR spectra
were recorded (as indicated) on Bruker 300, 400, or 600 MHz
spectrometer (Bruker, Billerica, MA) and are reported as
chemical shifts in ppm relative to TMS, calibrated to the signal
of the deuterated NMR solvent (300 and 400 MHz). Spin
multiplicities are reported as singlet (s), doublet (d), triplet
(t), quintet (qui), with coupling constants (J) given in hertz, or
multiplet (m). Broad peaks are marked as br. NMR
experiments (600 MHz) were performed on a Bruker Avance
III NMR spectrometer operating at 600.13 MHz proton
frequency. The instrument was equipped with a direct observe
5 mm BBFO smart probe. The experiments were performed at
298 K, and the temperature was calibrated using a methanol
standard showing accuracy within ±0.2 K. HRESI-MS was
performed on a QSTAR Pulsar (AB Sciex Switzerland GmbH,
Baden, Switzerland) spectrometer and are reported as mass-
per-charge ratio m/z. IR spectra were recorded on a
PerkinElmer Spectrum One Fourier transform infrared (FT-
IR) spectrometer (ATR, Golden Gate, PerkinElmer, Basel,
Switzerland). 1,2-Dioleoyl-3-trimethylammonium-propane
(DOTAP) was obtained from Corden Pharma Switzerland
LLC (Liestal, Switzerland). Glucose was purchased from Roth
AG, Switzerland. Dulbecco’s modified Eagle’s medium
(DMEM) high glucose was obtained from Sigma-Aldrich Co.
(St. Louis, MO) and supplemented with 10% FCS
(BioConcept, Allschwil, Switzerland) and penicillin (100
units/mL)−streptomycin (100 μg/mL) (Sigma-Aldrich Co.,
St. Louis, MO). Trypsin/EDTA (0.25%) was purchased from
Invitrogen, Life Technologies (Zug, Switzerland). FACS
buffer, composed of D-PBS (Sigma-Aldrich Co, St. Louis,
MO), was supplemented with 2% FCS and 0.1% NaN3
(Sigma-Aldrich Co., St. Louis, MO). The MTT reagent
comprised a 1:10 dilution (v/v) of a 5 mg/mL 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide stock
solution in DMEM. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide was purchased from Carl Roth
(Karlsruhe, Germany). SDS was purchased from Bio-Rad
Laboratories, Cressier, Switzerland. HCl and isopropanol were
obtained from Merck KGaA (Darmstadt, Germany).
The extrusion equipment consisted of 100 nm polycar-
bonate membranes (Whatman Nuclepore Track-Etched
Membranes, GE Healthcare Life Sciences, Buckinghamshire,
U.K.), filter supports (Whatman Drain Disc 10 mm PE, GE
Healthcare Life Sciences, Buckinghamshire, U.K.), and a hand
extruder (Avanti Mini Extruder, Avanti Polar Lipids, Inc., AL).
Particle size and ζ-potential measurements were performed
using a Delsa Nano C Particle Analyzer (Beckman Coulter,
Inc., Indianapolis, IN). Transmission electron microscopy
(TEM) was conducted using a CM-100 electron microscope
(Philips, Eindhoven, the Netherlands). Transfection experi-
ments and cytotoxicity experiments were conducted in 24-well
plates (TPP Tissue Culture Testplate 24, TPP Techno Plastic
Products AG, Trasadingen, Switzerland) and in 96-well plates
(TPP Tissue Culture Testplate 96F, TPP Techno Plastic
Products AG, Trasadingen, Switzerland), respectively. The
minicircle DNA was kindly provided by the University
Children’s Hospital Zürich, Switzerland. Statistical evaluation
was carried out using OriginPro 2018 (64-bit) SR1 b9.5.1.195
(Academic) (OriginLab Corporation, Northampton, MA).
Synthesis of Aminolipids. A small library of 12
multitailed aminolipids was obtained via reductive amination
of decanal or dodecanal with different amines, as depicted in
Figure 1. Briefly, the various amines representing the
headgroups of the respective aminolipids were mixed with
excess aldehyde (representing the tails) in dichloromethane
(DCM). The mixture was stirred for 3 h at RT, followed by the
addition of sodium triacetoxyborohydride (STAB) and further
stirred for 2−5 days at RT. Afterward, the solvent was
evaporated under reduced pressure. The obtained aminolipids
were then redissolved in 30 mL of DCM. Brine (30 mL) was
added, and the aminolipids were extracted three times with
DCM. The crude product was then purified using column
chromatography (silica) and a gradient of an appropriate
solvent system, e.g., DCM/MeOH or EtOAc/MeOH (e.g., 98:2
Figure 1. One-pot combinatorial synthesis of short-chain aminolipids
via double-reductive amination. (A) Double-reductive amination of
aldehydes with amines in dichloromethane (DCM) in the presence of
sodium triacetoxyborohydride (STAB) as a reducing agent. (B)
Briefly, amines (Am) are mixed with excess aldehyde (Ald) and
stirred at RT for 3 h followed by the addition of STAB. The reaction
continues under stirring at RT for 3−5 days. The obtained
aminolipids are then extracted using DCM/brine and then purified
by column chromatography (silica, DCM/MeOH 98:2 → 90:10). A
detailed description of the chemical synthesis and experimental
procedures is provided in the Supporting Information.
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to 90:10 (v/v)). The obtained aminolipid fractions were
checked for the presence of aminolipid using thin-layer
chromatography (TLC). Clean fractions containing the
aminolipid (according to TLC) with the correct mass
(determined by MS) were combined, and the solvent was
evaporated under reduced pressure. For the final drying step,
aminolipid samples were exposed to vacuum using an HV
pump for at least 2 days. Detailed descriptions and NMR plots
for each aminolipid can be found in the Supporting
Information.
Preparation of Aminolipid-Based Systems. DNA
Vector Delivery. Aminolipids in chloroform were combined
with chloroform stock solutions of cholesterol, DOPE, or
DOTAP (1:1 mol/mol) or a combination of either cholesterol
and DOTAP, or DOPE and DOTAP (aminolipid:helper:DO-
TAP = 5:4:1 (mol/mol)) in a glass vial. The (amino-)lipid
mixture in chloroform was subsequently dried under nitrogen
flow overnight. On the next day, the components were
rehydrated using 5% D(+)-glucose solution in Milli-Q ddH2O
to obtain a final DOTAP (or aminolipid-) concentration of 8
mM. Afterward, the mixtures were stirred and vortexed to
ensure complete rehydration of the (amino-)lipid components.
Following this step, the rehydrated mixtures were subjected to
five freeze−thaw cycles (i.e., frozen for 5 min using dry ice
followed by thawing for 5 min in a water bath at 62 °C). After
freeze−thawing, the (amino-)lipid mixtures were left at room
temperature (RT) for 3 h. Subsequently, the mixtures were
extruded 15 times through a Whatman Nuclepore Track-
Etched Membrane with a pore size of 0.1 μm using an Avanti
Mini Extruder.
Physicochemical Characterization of Aminolipid-
Based Systems. Directly after extrusion, the size, polydisper-
sity index (PDI), and ζ-potential of the aminolipid nano-
particles were measured using a Delsa Nano C Particle
Analyzer at RT, as described previously.37,38 Particle size and
PDI were determined using CONTIN data conversion after
measurement of the extruded nanoparticle preparation
(cDOTAP = 8 mM) using a 658 nm laser. Scattered light
was detected at an angle of 165°. ζ-Potential data were
converted using the Smoluchowski equation after measure-
ment of nanoparticles diluted 1:50 (v/v) in 5% glucose
solution at an angle of 15°. Transmission electron microscopy
(TEM) images of both pure lipid nanoparticles (LNPs) and
LNPs complexed with DNA were acquired on a CM-100
electron microscope (Philips, Eindhoven, the Netherlands).
Thus, samples were loaded on a carbon-coated copper grid and
counterstained using 2% uranylacetate solution. Excess
uranylacetate was removed and the grids were dried at RT
overnight prior to TEM imaging.
Cell Culture. HuH7 cells were cultured in high-glucose
DMEM, supplemented with 10% fetal calf-serum (FCS),
penicillin (100 units/mL), and streptomycin (100 μg/mL) at
37 °C and 5% CO2. For transfection experiments, the cells
were detached at 80−90% confluency using 0.25% trypsin/
EDTA (Invitrogen, Life Technologies, Zug, Switzerland) and
seeded in 24-well plates (TPP Tissue Culture Testplate 24,
TPP Techno Plastic Products AG, Trasadingen, Switzerland)
at a seeding density of 5 × 104 cells per well. For cytotoxicity
experiments, the cells were detached as for transfection
experiments and seeded in 96-well plates (TPP Tissue Culture
Testplate 96F, TPP Techno Plastic Products AG, Trasadingen,
Switzerland) at a seeding density of 104 cells per well.
Transfection Experiments. DNA Vector Delivery.
Twenty-four hours after seeding, the cells were transfected
with minicircle DNA (mcDNA) encoding for enhanced green
fluorescent protein (eGFP 1) under the control of a liver-
specific p3 promoter. Aminolipid−LNPs were combined with
DNA at the indicated ratios and amounts of DNA. Briefly,
aminolipid−LNPs and DNA were diluted in separate 1.5 mL
Eppendorf tubes in 5% glucose solution. After gentle mixing,
the contents of the tubes were combined, and the mixture was
left for 30 min on the bench to allow for formation of
complexes between aminolipid−LNPs and DNA. After
incubation of the DNA with the LNPs, 50 μL of LNP/DNA
nanoparticles was added to the cell culture medium (final
volume: 1 mL). The ratios of the combination of DNA with
LNPs are depicted as the amount of DNA in micrograms and
the final concentration of LNPs (μM) in cell culture medium
during transfection experiments. The reason for this depiction
is that Lipofectamine 3000, whose composition is unknown,
was included in the experiment according to the manufac-
turer’s protocol. The amount of Lipofectamine 3000 for
transfection experiments was calculated based on an approach
relying on the volume of Lipofectamine 3000 in microliters per
weight of DNA in micrograms (v/w). This volume per weight
approach was maintained throughout the whole study,
resulting in a uniform depiction of all samples. Even though
no concentration data is available for Lipofectamine 3000, and
therefore, it is technically not correct to provide any
concentrations for Lipofectamine 3000, we employed an
arbitrary concentration for Lipofectamine 3000 assuming that
1 μL of Lipofectamine 3000as used according to the
manufacturer’s instructionsis equivalent to 1 μL of
DOTAP:chol LNPs. N/P ratios are indicated where applicable.
Transgene Expression Analysis. Confocal Laser Scan-
ning Microscopy. Live-cell images were acquired on an
Olympus FV-1000 inverted confocal fluorescence microscope
(Olympus Ltd., Tokyo, Japan) 24 and 48 h after transfection to
qualitatively assess the transfection efficiency. GFP was excited
at 488 nm, and emission was recorded at 516 nm using a
UPlanSApo 10× objective (numerical aperture, 0.40).
Flow Cytometry. Transfection efficiency and transgene
expression were both measured using an FACS Canto II flow
cytometer (Becton Dickinson, San Jose, CA) 48 h after
transfection. Briefly, the cells were detached using 0.25%
trypsin/EDTA (m/V) for 7 min. Subsequently, trypsin
digestion was stopped by the addition of DMEM cell culture
medium and the cell suspension was transferred to a 1.5 mL
Eppendorf tube. The cell suspension was centrifuged
(Eppendorf 5424 R Centrifuge, Eppendorf AG, Hamburg,
Germany) at 200g for 5 min at RT. The supernatant was
aspirated, the cells were suspended in FACS buffer (D-PBS,
2% FCS, 0.1% NaN3), and %GFP-positive cells and mean
fluorescence intensity (MFI) were measured after excitation at
488 nm. The fluorescence signal of cells expressing GFP was
detected in fluorescence channel FL1 (505LP530/30).
Statistical evaluation of the obtained flow cytometry data was
done using FlowJo Vx software (TreeStar, Ashland, OR). MFI
values were calculated from GFP-positive cells.
Cytotoxicity Experiments. The HuH7 cells were treated
with aminolipid−LNPs at various concentrations 24 h after
seeding. Four hours after treatment, the medium containing
LNPs was aspirated and replaced by a fresh medium. Twenty-
four hours after treatment, the medium was aspirated and
replaced by a medium containing 0.5 mg/mL 3-(4,5-
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dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT). The 96-well plates were then incubated (37 °C, 5%
CO2) for 2 h to allow formation of formazan crystals.
Afterward, the medium was aspirated and the insoluble
formazan crystals were solubilized using a mixture of 3%
SDS in H2O and 40 mM HCl in isopropanol (1:6, v/v). The
plates were then shaken for 2 h, followed by absorption
measurement using a 96-well plate reader (SpectraMax M2e
Microplate Reader, Molecular Devices LLC, San Jose, CA) at
570 (formazan signal) and 670 nm (background).
Statistical Evaluation. Statistical evaluation was done
using OriginPro 2018 (64-bit) SR1 b9.5.1.195 (Academic)
Software (OriginLab Corporation, Northampton, MA). A
minimum of three independent measurements were used for
statistical evaluation.
Zebrafish Embryo In Vivo Trials. Zebrafish culture and
injection were carried out as described previously.39 Briefly,
zebrafish embryos of the Tg(kdrl:EGFP)40 line were raised
under standard conditions in accordance with Swiss animal
welfare regulations. Fish were maintained at 28 °C in zebrafish
culture media supplemented with 1-phenyl-2-thiourea (PTU).
Calibrated volumes of 1 nL sample were injected into the Duct
of Cuvier (80 pg DNA, 0.64 pmol DOTAP) using a
micromanipulator (Wagner Instrumentenbau KG, Schöffen-
grund, Germany), a pneumatic PicoPump PV830 (WPI,
Sarasota, Florida), and a Leica S8APO microscope (Leica,
Wetzlar, Germany). Imaging was carried out 4 and 24 h post-
injection using a LEICA POINT SCANNING CONFOCAL
“SP5-II-MATRIX” (Leica, Wetzlar, Germany) equipped with a
25× HCX IRAPO L (NA 0.95) objective. Image analysis was
carried out using Fiji ImageJ v. 1.52n.
■ RESULTS AND DISCUSSION
Combinatorial Synthesis of Aminolipids. The aim of
this study was the design, synthesis, and screening of novel
types of short-chain aminolipids to maximize the DNA vector
delivery of DOTAP:chol lipoplexes. To create a small lipid
library for this proof-of-concept study, we developed a
straightforward one-pot combinatorial synthesis based on a
double-reductive amination strategy (Figure 1). A combination
of various amines and aldehydes in the presence of the
reducing agent sodium triacetoxyborohydride (STAB) resulted
in the respective short-chain aminolipids with different
headgroups and lipid tails.
An overview of selected building blocks as starting materials
(i.e., amines and aldehydes) is given in Figure 2A−C. Based on
previous findings by our group that short-chain (C8−C12)
lipid-like materials result in improved nucleic acid delivery,
decanal (C10) and dodecanal (C12) were selected as building
blocks for lipid tails. In addition to aliphatic amines,
heterocyclic amines were selected as headgroups based on
previous reports that inclusion of aromatic or heterocyclic rings
into transfection reagents can increase the transfection
efficiency.41−45 To test whether these principles also apply to
DNA vector delivery based on DOTAP:chol lipoplexes,
different building blocks were selected and combined to afford
the corresponding aminolipids (see the Supporting Informa-
tion for synthesis details and aminolipid characterization). For
example, aminolipid AL-A10 was synthesized using 3-
methoxypropylamine (A) and decanal (C10).
In summary, 12 different short-chain aminolipids were
successfully synthesized in high yield using a versatile two-step
one-pot procedure. This combinatorial synthesis is easy to
perform and fully scalable.
Physicochemical Characterization of Aminolipid-
Containing Systems. The obtained aminolipids were
incorporated into DOTAP-based systems in a 1:1 ratio
(mol/mol) using a lipid-film rehydration and extrusion
method, as described in the Supporting Information. The
results of the physicochemical characterization of amino-
lipid:DOTAP systems are shown in Figure 3. Most amino-
lipid:DOTAP systems showed hydrodynamic diameters in the
range of 54−79 nm along with a monodisperse size
distribution, as indicated by a polydispersity index (PDI)
below 0.2 (Figure 3A,B). The largest diameter was measured
for the conventional formulation based on DOTAP:chol
(108.2 ± 0.6 nm) followed by the AL-H10-containing system
(102.0 ± 5.9 nm). The smallest diameter was measured for the
AL-C10 system (53.5 ± 2.5 nm) followed by the AL-B10
system (53.8 ± 2.0 nm). Both AL-A10 and AL-A12 systems
showed hydrodynamic diameters of 61.5 ± 1.0 and 63.6 ± 0.8
nm and PDI values of 0.185 and 0.181, respectively.
Interestingly, incorporation of C10-based aminolipids always
resulted in smaller systems compared to their C12 counterparts.
All measurements were carried out in triplicate.
The ζ-potential measurements for the obtained DOTAP-
based systems revealed a positive surface charge in the range of
18−53 mV (Figure 3C). The highest ζ-potential was found for
the formulation including AL-B10 with a highly positive value
of 52.27 ± 2.80 mV followed by the AL-A12 system (43.66 ±
1.19 mV). The AL-B12 system showed the lowest ζ-potential
with a value of 17.97 ± 4.28 mV followed by the AL-D10
system (21.29 ± 3.48 mV). The AL-A10 system showed a
similar ζ-potential to DOTAP:chol (24.86 ± 3.26 vs 28.21 ±
4.31 mV). A highly positive ζ-potential (>30 mV) is indicative
of a high colloidal stability resulting from electrostatic repulsive
forces that prevent aggregation of particles.46,47 Good colloidal
stability can still be assumed for systems with ζ-potentials in
the range of ±30 mV. This in contrast to a range from 0 to ±5
mV, which is indicative of particle agglomeration and
instability.48 In fact, during the time course of this study, no
precipitation was observed for any formulation. All measure-
ments were carried out in triplicate.
Representative TEM images of DOTAP:chol and the AL-
A12-containing system are displayed in Figure 3D,E. Both
Figure 2. Building blocks for the combinatorial synthesis of
aminolipids. (A) Aliphatic amine compounds including (A) 3-
methoxypropylamine, (B) 3-aminopropan-1-ol, (C) 3-aminopro-
pane-1,2-diol, (D) N,N′-dimethylethylenediamine, and (E) 1,3-
diaminopropane. (B) Aromatic and heteroaromatic amine com-
pounds including (F) benzylamine, (G) 1H-imidazol-2-ylmethan-
amine, and (H) 4-(aminomethyl)pyridine. (C) Aldehydes decanal
(C10) and dodecanal (C12) as building blocks for lipid tails.
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systems resulted in spherical assemblies with diameters of
82.81 ± 24.64 nm (DOTAP:chol) and 46.13 ± 8.85 nm (AL-
A12 containing system), which is slightly smaller than the
diameters based on dynamic light scattering (DLS). In
conclusion, short-chain aminolipids can be successfully
incorporated into DOTAP-based systems, thereby influencing
the size and charge of the resulting particles.
Assessment of DNA Vector Delivery In Vitro. To assess
the efficiency of DNA delivery, we selected an advanced DNA
vector type, i.e., minicircle DNA, which has clear advantages
over plasmid DNA. Several research groups have demonstrated
that the use of minicircle DNA results in high transfection
efficiencies and long-lasting transgene expression.49−51 There-
fore, a minicircle DNA encoding the reporter gene for green
Figure 3. Physicochemical characterization of DOTAP systems combined with short-chain aminolipids. (A) Hydrodynamic diameter (nm), (B)
polydispersity index (PDI), and (C) ζ-potential (mV) for aminolipid-containing DOTAP systems compared to the conventional
DOTAP:cholesterol (chol) system at a 1:1 ratio (mol/mol). (D) Transmission electron microscopy (TEM) of DOTAP:chol and (E) AL-A12-
containing systems.
Figure 4. In vitro assessment of transfection efficiency and cytotoxicity of lipoplex systems. (A) Heat map representing the transfection efficiency of
aminolipid-containing DOTAP lipoplexes compared to conventional DOTAP:cholesterol (chol) composed lipoplexes. Transfection efficiency was
assessed by means of percentage of GFP-positive cells and mean fluorescence intensity (MFI) of GFP expression using flow cytometry. The
obtained results were allocated to different groups (color code) based on the quartiles of %GFP-positive cells and MFI. Representative confocal
images of HuH7 cells transfected with (B) DOTAP:chol or (C) AL-A12-containing lipoplexes entrapping minicircle DNA coding for GFP (scale
bar = 400 μm). (D) Cytotoxicity of aminolipid-containing DOTAP lipoplexes compared to conventional DOTAP:chol lipoplexes by means of
lethal concentrations (LC 10/50/90) resulting in 90/50/10% cell viability, respectively.
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fluorescent protein (GFP) was complexed using DOTAP:chol
and aminolipid-containing systems. The lipoplexes were not
PEGylated to reduce complexity, thereby allowing us to
attribute observed effects directly to the formulation
components. Resulting lipoplexes were used for transfection
of human liver-derived HuH7 cells in vitro (Table S1). A color-
coded summary of the transfection screening is shown in
Figure 4A. DOTAP:chol lipoplexes (at 1 μg DNA and 8 μM
lipid concentration) resulted in 5.7% GFP-positive cells.
Compared to the conventional DOTAP:chol system, incorpo-
ration of various aminolipids based on aliphatic amines
resulted in improved transfection efficiencies (i.e., AL-A to
AL-D). For example, AL-B12 and AL-C12 systems resulted in
8.6 and 6.0% GFP-positive cells, respectively. The lipoplexes
containing AL-A10 (7.7%) and AL-A12 (10.3%) showed a
significantly increased transfection efficiency compared to
DOTAP:chol (p < 0.001), which was even more distinct at 2
μg DNA and 16 μM lipid concentration with 28.7% (AL-A10)
and 31.5% (AL-A12) compared to 13.2% (DOTAP:chol).
Moreover, AL-A12 showed 72% of the transfection efficiency
of Lipofectamine 3000 (47.5% GFP-positive cells). In contrast,
DOTAP:chol was only 30% as efficient as Lipofectamine 3000.
A statistically significant (p < 0.001) increase in transgene
expression (i.e., assessed based on mean fluorescence intensity
(MFI)) compared to DOTAP:chol was only observed for AL-
A12. While DOTAP:chol only resulted in 10% of the gene
expression achieved with Lipofectamine 3000, AL-A12-based
lipoplexes exhibited 20% of the transgene expression of
Lipofectamine 3000. The replacement of aliphatic amine
headgroups with heterocyclic groups (i.e., AL-F10, AL-G10,
and AL-H10) to improve the fusogenic properties (as
previously described52) did not maximize the efficacy (i.e., %
GFP-positive cells) of DOTAP-based lipoplexes (Figure 4A).
However, AL-F10 (at 1 μg DNA and 8 μM lipid
concentration) resulted in the highest transgene expression
among all aminolipids of the combinatorial library. It is
tempting to speculate that AL-F10 enhanced the endosomal
escape in transfected cells, resulting in increased GFP
expression. Due to the small number of investigated
heterocyclic headgroups, further studies are warranted to
clarify if such a strategy is applicable for DOTAP-based
lipoplexes.
To further improve the understanding of how the amino-
lipids’ structural parameters influence the transfection
efficiency, specific compounds were selected for a structure−
activity relationship (SAR) study (Figure S37). Aminolipids
consisting of a bifunctional methoxy headgroup (AL-A10, AL-
A12) showed significantly (p < 0.001) higher transfection
efficiencies and transgene expression levels compared to
aminolipids with a bifunctional hydroxy headgroup (AL-B10,
AL-B12). SAR analysis of tail groups revealed significantly
higher transfection efficiencies (p < 0.1) and transgene
expression levels (p < 0.001) for aminolipids consisting of
C12 tails compared to aminolipids consisting of C10 tails, as
demonstrated by the superiority of AL-A12 over AL-A10. Due
to the poor transfection efficiency of many of the tested
aminolipids, an in-depth SAR analysis focusing on headgroups
could not be performed. Further experiments with an
expanded range of aminolipid tail lengths and alternative
headgroups are needed to improve our understanding on how
small changes in lipid tail length influence the delivery of DNA
vectors.
In conclusion, the highest transfection efficiency was
achieved using AL-A12 lipoplexes with a 2-fold increased
number of GFP-positive cells as well as significantly higher
transgene expression compared to DOTAP:chol lipoplexes.
Representative confocal laser scanning microscopy images of
HuH7 cells transfected with DOTAP:chol lipoplexes and AL-
A12-containing lipoplexes are shown in Figure 4B,C,
respectively. An increased efficiency results in a lower dose
of the potentially cytotoxic transfection reagent that needs to
be administered while maintaining the same effect and is
consequently mitigating side effects of the gene therapy.
Moreover, the known composition of these lipoplexes allows
for surface modification (e.g., PEGylation), which is difficult to
achieve for the proprietary formulation Lipofectamine 3000.
Cytotoxicity of Lipoplex Systems. Figure 4D displays
the results of the cell viability assessment. Several aminolipids
with aliphatic headgroups and improved transfection efficacy
also resulted in enhanced cytotoxic effects (i.e., AL-B to AL-D).
Generally, it was observed that aminolipids derived from C12
Figure 5. Assessment of in vivo transfection efficiency of the lead lipoplex system containing aminolipid AL-A12. Evaluation of lipoplex
biodistribution and transfection efficiency in vivo in the zebrafish model. Confocal imaging (maximum intensity projections) of transgenic zebrafish
embryos with GFP expressing vasculature endothelial cells was performed 4 and 24 h post-injection with fluorescent DOTAP:chol or AL-A12-
based lipoplexes entrapping plasmid DNA encoding for RFP. Representative maximum intensity projections of a series of three images are shown
(4 h post-injection). Displayed are the merged images, the vasculature expressing GFP (green), the DiD-labeled lipoplexes (blue), and the reporter
gene expression (RFP, red). AL-A12 promoted a qualitatively higher gene expression than DOTAP:chol-based lipoplexes h. Scale bars = 80 μm.
The right graphs show the quantitative image analysis using Fiji ImageJ of the total area in pixels (top) and the percentage of the area (bottom) of
the RFP expression determined 4 and 24 h post-injection of DOTAP:chol (black) and AL-A12-based lipoplexes (gray). The results were not
statistically significant at p < 0.05.
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aldehydes are less toxic than aminolipids derived from C10
aldehydes (Tables S2 and S3). For example, AL-A10 systems
showed a toxicity comparable to DOTAP:chol while at the
same time having increased DNA delivery efficacy. Interest-
ingly, the lead aminolipid AL-A12 demonstrated lower toxicity
across the entire dose range than DOTAP:chol. Up to a
concentration of 16 μM total lipid, AL-A12 systems resulted in
cell viabilities of approximately 80%. At 64 μM total lipid, AL-
A12 still resulted in cell viabilities of up to 50%. These results
clearly indicate a lower cytotoxic potential for AL-A12-
containing lipoplexes than for DOTAP:chol. Lipoplex systems
composed of aminolipids with heterocyclic headgroups caused
similar or reduced toxicity. The lowest cytotoxic effects were
observed using AL-F10-based lipoplexes, thereby confirming
that inclusion of aromatic or heterocyclic rings into a
transfection reagent can mitigate cytotoxic effects.42−45
Conclusively, the lead structures from our transfection
screening AL-A12 and AL-F10 (most GFP-positive cells and
highest MFI) also outperformed the other aminolipids in the
cytotoxicity screening assay. This confirms the generally
accepted dogma that low cytotoxic side effects are a
prerequisite to achieve high transfection rates.53
Assessment of DNA Vector Delivery In Vivo. Due to its
high transfection efficiency (% transfected cells) and low
toxicity in vitro, AL-A12 was selected as lead aminolipid for the
in vivo evaluation in the zebrafish embryo model, a validated in
vivo tool to assess lipid-based delivery systems.39,54−56 To
assess the systemic circulation of AL-A12 and DOTAP:chol
lipoplexes, the fluorescent lipid 1,1′dioctadecyl-3,3,3′,3′-
tetramethylindodicarbocyanine (DiD) was incorporated as a
tracer. To evaluate the utility of developed lipoplexes for in vivo
gene delivery, lipoplexes entrapped DNA encoding for RFP.
Both lipoplex systems were injected intravenously into
transgenic zebrafish embryos expressing GFP in their
vasculature. Biodistribution and reporter gene expression
were analyzed 4 and 24 h post-injection using confocal
microscopy (Figure 5).
As expected for cationic systems, both lipoplexes associated
with endothelial cells with preference for venous vasculature.57
The evaluation of reporter gene expression confirmed the
fluorescence distribution patterns. AL-A12-based lipoplexes as
well as DOTAP:chol resulted in RFP expression in endothelial
cells 4 h post-injection with stronger expression in venous
vasculature. Both qualitative confocal imaging and the image
analysis confirmed a higher gene expression in vivo for AL-A12
compared to DOTAP-based lipoplexes. Further in vivo studies
are needed to assess the potential to target actively growing
tumor blood vessels as shown for other positively charged lipid
systems.58
■ CONCLUSIONS
In recent decades, DOTAP:chol lipoplexes have been
investigated in several clinical trials for the delivery of DNA
vectors. However, none of these studies has advanced to a late
clinical stage due to poor outcomes with respect to efficacy.
The present study describes the design and one-pot synthesis
of short-chain aminolipids enabling incorporation into
DOTAP-based lipoplexes to maximize DNA vector delivery.
The structure−activity relationship analysis revealed methoxy
headgroups to be superior to hydroxy headgroups. Further-
more, C12 lipid tails promote higher transfection efficiencies
than C10 tails. The DNA vector transfection ability in HuH7
cells in vitro was significantly increased using various
aminolipids (e.g., AL-A12). In addition, incorporation of
selected aminolipids clearly mitigated the cytotoxicity. In vivo
studies in zebrafish embryos showed higher gene expression
using the lead lipoplex system based on AL-A12 compared to
conventional DOTAP:chol lipoplexes.
In conclusion, our presented one-pot combinatorial syn-
thesis is a versatile approach to create lipid libraries for the
development of DNA delivery systems. The combination of
DOTAP with short-chain aminolipids promotes efficient DNA




The Supporting Information is available free of charge at
https://pubs.acs.org/doi/10.1021/acsomega.0c03303.
Details on materials and methods; results of the
synthesis, transfection, and cytotoxicity of aminolipids;
and statistical data (PDF)
■ AUTHOR INFORMATION
Corresponding Author
Jörg Huwyler − Division of Pharmaceutical Technology,
Department of Pharmaceutical Sciences, University of Basel,
4056 Basel, Switzerland; orcid.org/0000-0003-1748-5676;
Phone: +41 61 207 15 13; Email: joerg.huwyler@unibas.ch
Authors
Jonas Buck − Division of Pharmaceutical Technology,
Department of Pharmaceutical Sciences, University of Basel,
4056 Basel, Switzerland
Dennis Mueller − Department of Chemistry, University of
Fribourg, 1700 Fribourg, Switzerland
Ute Mettal − Department of Chemistry, University of Fribourg,
1700 Fribourg, Switzerland; Department of Bioresources of the
Fraunhofer Institute for Molecular Biology and Applied Ecology,
Institute for Insect Biotechnology, Justus-Liebig-University
Giessen, 35392 Giessen, Germany
Miriam Ackermann − Department of Chemistry, University of
Fribourg, 1700 Fribourg, Switzerland
Hiu Man Grisch-Chan − Division of Metabolism and
Children’s Research Center, University Children’s Hospital
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